MADISON, Wis., Nov. 12, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics
International, Inc. (CDI) (Nasdaq:ICEL), today announced that Susan A.
Willetts was elected to the company’s board of directors, effective
November 6, 2014. Ms. Willetts also will serve as a member of the CDI
board’s audit committee.
Ms. Willetts has been an advisory director of Goldman, Sachs & Co.
since July 2011. Prior to July 2011 she was a partner. She joined the
firm in the Investment Banking Division in 1989, was named managing
director in 1996 and partner in 2002. Prior to joining Goldman Sachs,
Ms. Willetts worked at Microdot for five years, most recently as
treasurer, and at Northwest Industries for three years. She is on the
board of the Chicago Botanic Garden, where she served as chair from
2009 to 2012. Ms. Willetts has been a member of the Economic Club of
Chicago since 2004 and became a member of The Chicago Network in 2008.
She served on the board of The Field Museum from 1998 to 2006. She
earned a BA from Dartmouth in 1977 and an MBA from Northwestern
University in 1981.
Susan Willetts said, “Innovation is critical in the field of human
healthcare, and I believe that CDI is uniquely positioned to make a
significant impact with its technology, patent portfolio and deep
expertise. I am pleased to be joining CDI’s board of directors, and I
look forward to helping guide the growth of this expanding company.”
Bob Palay, chief executive officer and chairman of the board of CDI,
said, “Susan brings to our board deep business experience gained from
many years in successful leadership positions. She is a tremendous
addition to our board, and we are pleased to have a person of her
accomplishments join us.”
About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer and
manufacturer of fully functioning human cells in industrial quantities
to precise specifications. CDI’s proprietary iCell Operating System
(iCell O/S) includes true human cells in multiple cell types (iCell
products), human induced pluripotent stem cells (iPSCs) and custom
iPSCs and iCell products (MyCell Products). CDI’s iCell O/S products
provide standardized, easy-to-use, cost-effective access to the human
cell, the smallest fully functioning operating unit of human biology.
Customers use our iCell O/S products, among other purposes, for drug
discovery and screening; to test the safety and efficacy of their small
molecule and biologic drug candidates; for stem cell banking; and in
the research and development of cellular therapeutics. CDI was founded
in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell
research at the University of Wisconsin-Madison. CDI’s facilities are
located in Madison, Wisconsin, with a second facility in Novato,
California. See www.cellulardynamics.com.